Home
Press releases
Press releases
Recent press, briefings and insights helping you stay informed on AliveDx newest launch.
-
AliveDx Receives IVDR-CE Mark for Multiplexed Assay to Accurately Detect Celiac Disease (CD) on the MosaiQ® System
Eysins, September 3, 2024 At AliveDx, our mission is to empower diagnostic insights, transform patient care, and innovate for life. We are excited and proud to announce AliveDx has received IVDR-CE mark certification for its multiplexed MosaiQ AiPlex™ CD microarray
-
AliveDx Announces Turnkey Solution for Precise, Automated Autoimmune Diagnostics
Eysins Switzerland 29 July 2024 AliveDx, a global in vitro diagnostics company that aims to transform patient care, today announced LumiQ™ – an innovative, automated immunofluorescence assay (IFA) solution. With this portfolio expansion, AliveDx can offer customers a differentiating, turnkey
-
AliveDx Receives IVDR CE Mark for Groundbreaking Microarray Immunoassay in Allergy Diagnostics
Eysins, Switzerland, 29 July 2024 AliveDx (“Company”) is proud to announce it has received IVDR CE mark for its groundbreaking microarray immunoassay, designed for the detection of a specific IgE directed to a protein allergen in human serum. This is
-
AliveDx receives IVDR Certification of its Manufacturing Sites in Switzerland and United Kingdom
Eysins, 6 November 2023 — AliveDx a global in vitro diagnostics company headquartered in Eysins, Switzerland, today announced it has now received IVDR Certification for both its state-of-the-art manufacturing facilities located in Eysins, Switzerland and Edinburgh, United Kingdom. AliveDx is
-
AliveDx receives three IVDR CE marks for its Multiplexed Autoimmune Diagnostics Solution
AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD). Eysins, 30 October 2023 — AliveDx is proud to announce it has received three CE Marks for: Its MosaiQ Centromere Protein B (CENP-B)
-
Quotient Limited Selected to Join the World Economic Forum New Champions Community
JERSEY, Channel Islands, September 8th 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced it was selected by the World Economic Forum to join their New Champions Community. “We are delighted
-
Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies
JERSEY, Channel Islands, 24 August 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices (Sanquin), headquartered in Amsterdam,
-
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
JERSEY, Channel Islands, June 8, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner
-
Quotient Limited Announces Opening of Office in Dubai, United Arab Emirates
Diversified global presence key to Company’s go-to-market strategy Strengthened geographical expansion with distributor strategy model to better support customers in the region JERSEY, Channel Islands, May 17, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company,
-
Quotient Limited to Host Key Opinion Leader Webinar on its MosaiQ™ Solution
JERSEY, Channel Islands, May 12, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it will host a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and
